Form 4: Karyopharm GC Awarded 43,650 RSUs

Karyopharm Therapeutics' SVP, General Counsel & Secretary, Michael Mano, was awarded 43,650 restricted stock units vesting in December 2026.

Summary

• Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics Inc. (KPTI), acquired 43,650 shares of common stock.
• The acquisition occurred on October 15, 2025, at a price of $0 per share.
• The shares represent an award of restricted stock units (RSUs) under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
• Each RSU converts into one share of Karyopharm Therapeutics Inc. common stock.
• The RSUs will vest 100% on December 31, 2026.
• Following this transaction, Michael Mano beneficially owns 65,075 shares of common stock.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a key executive is generally a positive sign for corporate governance and management alignment with shareholder interests, though it does not directly reflect operational or financial performance.

Positives

• The award of restricted stock units aligns the interests of a key executive, Michael Mano, with those of shareholders, as the value of the award is tied to the company's stock performance.
• The equity incentive plan serves as a retention mechanism for senior management.

Negatives

• The award does not represent an immediate cash inflow for the executive, as it is subject to a vesting period.
• The value of the award is contingent on the future stock price of Karyopharm Therapeutics Inc.

Risks

• The value of the restricted stock units is subject to market fluctuations of Karyopharm Therapeutics Inc.'s common stock.
• The RSUs are subject to a vesting schedule, meaning the executive must remain employed until December 31, 2026, to fully realize the award.

Future Outlook

The awarded restricted stock units are scheduled to vest 100% on December 31, 2026, indicating a future milestone for the executive's compensation realization.

Industry Context

The award of restricted stock units is a common practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to attract, retain, and incentivize key personnel by linking their compensation to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the biotech and broader corporate sectors, aligning executive incentives with long-term shareholder value.
• The vesting schedule, with a 100% vest on a future date, is typical for such awards, promoting executive retention and sustained performance over a defined period.

Corporate Governance

Stakeholder Impact

• Shareholders: The award of RSUs to a senior executive is intended to align management's interests with those of shareholders, potentially leading to better long-term performance.
• Employees: This transaction reflects the company's compensation strategy, which may influence other employees' expectations regarding equity awards.

Next Steps

• The restricted stock units will vest on December 31, 2026, at which point they will convert into common stock.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Michael Mano, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Insider Transaction, Form 4